版本:
中国

BRIEF-Threshold Pharmaceuticals reports Q1 loss per share of $0.07

May 15 Threshold Pharmaceuticals Inc

* Threshold Pharmaceuticals reports first quarter financial results

* Definitive merger agreement between Threshold and Molecular Templates expected to close mid-2017

* Qtrly loss per share $0.07

* Initiation of phase 1 clinical trial of Evofosfamide in combination with Ipilumumab on track to start in mid-2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐